๐ŸŽ Black Friday: 50% off Unlimited and 30% off Pro annual plans

Carter Gould

Stock Analyst at Cantor Fitzgerald

(4.44)
# 1,213
Out of 5,189 analysts
654
Total ratings
54.1%
Success rate
7.3%
Average return

Stocks Rated by Carter Gould

Merck & Co.
Nov 12, 2026
Reiterated: Hold
Price Target: $155
Current: $133.72
Upside: +15.91%
Amgen
Nov 3, 2026
Reiterated: Hold
Price Target: $440 → $465
Current: $435.64
Upside: +6.74%
Pfizer
Nov 3, 2026
Reiterated: Hold
Price Target: $28
Current: $27.40
Upside: +2.19%
Vertex Pharmaceuticals
Nov 2, 2026
Reiterated: Buy
Price Target: $595 → $619
Current: $515.02
Upside: +20.19%
AbbVie
Nov 1, 2026
Reiterated: Buy
Price Target: $290 → $325
Current: $286.20
Upside: +13.56%
Eli Lilly and Company
Nov 1, 2026
Reiterated: Buy
Price Target: $1,440 → $1,600
Current: $1,347.11
Upside: +18.77%
Regeneron Pharmaceuticals
Nov 1, 2026
Reiterated: Buy
Price Target: $795 → $980
Current: $920.69
Upside: +6.44%
Bristol-Myers Squibb Company
Oct 29, 2026
Reiterated: Hold
Price Target: $53
Current: $58.80
Upside: -9.86%
Gilead Sciences
Oct 29, 2026
Reiterated: Buy
Price Target: $155 → $175
Current: $166.43
Upside: +5.15%
Vaxcyte
Oct 12, 2026
Reiterated: Buy
Price Target: $120
Current: $55.39
Upside: +116.65%
Reiterated: Buy
Price Target: n/a
Current: $50.78
Upside: -
Rated: Hold
Price Target: n/a
Current: $249.59
Upside: n/a
Rated: Hold
Price Target: n/a
Current: $10.72
Upside: n/a
Rated: Hold
Price Target: n/a
Current: $47.00
Upside: n/a
Rated: Hold
Price Target: n/a
Current: $19.19
Upside: n/a
Rated: Buy
Price Target: $9
Current: $0.8707
Upside: n/a
Reiterated: Buy
Price Target: $12
Current: $2.34
Upside: n/a
Reiterated: Buy
Price Target: $160
Current: $150.57
Upside: n/a
Rated: Hold
Price Target: $160
Current: $155.89
Upside: n/a
Initiated Coverage: Buy
Price Target: $37
Current: $141.33
Upside: n/a
Initiated Coverage: Buy
Price Target: โ‚ฌ84.81
Current: โ‚ฌ146.45
Upside: n/a
Reiterated: Hold
Price Target: $82 → $86
Current: $114.63
Upside: n/a
Upgraded: Hold
Price Target: $94
Current: $554.73
Upside: n/a
Downgraded: Hold
Price Target: $16 → $4
Current: $1.95
Upside: n/a
Reiterated: Hold
Price Target: $6 → $2.8
Current: $6.14
Upside: n/a